Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
In both the presence and absence of erastin, SRS16-86 (1 μM) reduces ferroptosis in HT-1080 cells and NIH 3T3 cells for a duration of 24 hours [2].
|
---|---|
ln Vivo |
Mice treated with SRS16-86 (intraperitoneal injection, 2 mg/kg; 15 minutes prior to surgery) are protected against both structural organ damage and functional acute renal failure after ischemia-reperfusion injury (IRI) [2]. When it came to avoiding renal IRI, SRS16-86 (ip; 2 mg/kg; 4 weeks) in combination with [Nec-1+SfA] was more effective than [Nec-1+SfA] dual therapy. In the plasma of IRI mice models, the addition of SRS16-86 can lower serum urea and serum creatinine levels [2]. Rats with spinal cord injuries who receive an intraperitoneal injection of SRS16-86 (15 mg/kg, once daily for seven days) had reduced levels of inflammatory adhesion factors and pro-inflammatory cytokines in their injured spinal cords [3].
|
Animal Protocol |
Animal/Disease Models: Renal IRI model
Doses: 2 mg/kg; 15 min before the onset of surgery Route of Administration: intraperitoneal (ip)injection; 2 mg/kg; 15 min before the onset of surgery Experimental Results: Was protective from renal IRI. Animal/Disease Models: Renal IRI model Doses: 2 mg/kg Route of Administration: Combination with Necrostatin-1/Sanglifehrin A; 2 mg/kg; 4 weeks Experimental Results: Further increased the protective effect of [Necrostatin-1/Sanglifehrin A] combination therapy in renal IRI model. |
References |
[1]. Sam Hofmans, et al. Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. J Med Chem. 2016 Mar 10;59(5):2041-53.
[2]. Andreas Linkermann, et al. Synchronized renal tubular cell death involves ferroptosis.Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16836-41. [3]. Yan Zhang, et al. Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. Brain Res. 2019 Mar 1;1706:48-57. |
Molecular Formula |
C26H32N4O2
|
---|---|
Molecular Weight |
432.56
|
CAS # |
1793052-96-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O(C(C)(C)C)C(C1=CC=C(C(=C1)/N=C\C1=CN=CN=C1)NC12CC3CC(CC(C3)C1)C2)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 33.33 mg/mL (77.05 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.78 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (1.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3118 mL | 11.5591 mL | 23.1182 mL | |
5 mM | 0.4624 mL | 2.3118 mL | 4.6236 mL | |
10 mM | 0.2312 mL | 1.1559 mL | 2.3118 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.